Sanofi CEO Paul Hudson’s latest M&A gambit adds new eczema drug in $1.5B buyout. And he’s steering back into a market maelstrom
Around the same time that Sanofi CEO Paul Hudson was engineering a $3.7 billion buyout of Principia to add a late-stage multiple sclerosis drug to the pipeline last August, the team at Kymab was posting upbeat remarks about its mid-stage data on their rival OX40L drug for atopic dermatitis. Now Hudson has come back in to ink a $1.45 billion deal to buy Kymab out and add that to the late-stage immuno-inflammation pipeline as well.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.